ERBB2 and cancer: This hypothesis is supported by studies in other cancer models, including an orthotopic GBM model, where dual-targeted Her-2/IL-13Rα2 CAR T-cells demonstrated superior tumor suppression and survival enhancement compared to treatments with monospecific CAR T-cells, whether applied solo or in combination [115].